LUCD Lucid Diagnostics Inc.
$0.44▼ -12.50%
Healthcare
Other
Volume 10.15M
Avg Volume (10D) 22.56M
Key Metrics & Fundamentals
Market Cap
$83.65M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.30 - 1.63
% vs 50 MA
-41.52%
% vs 200 MA
-57.70%
RSI-14
37.1
MACD Histogram
+0.0000
Beta (1Y vs SPY)
1.07
Free Cash Flow
-$11.32M
Gross Rev
$1.47M
Gross Profit
$29,000
EBITDA
-$11.46M
COGS
$1.45M
Operating Exp
$12.83M
Operating Income
-$12.80M
EBIT
-$12.80M
Pretax Income
-$11.69M
Net Income
-$11.69M
EPS (Diluted)
-0.08
Price & Volume History
Loading chart…
Recent News
BC-Most Active Stocks
Associated Press · Oct 23, 2026 10:30 AM ET
Top Premarket Gainers
MT Newswires · Oct 23, 2026 7:10 AM ET
Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing
PR Newswire · Oct 22, 2026 4:20 PM ET
Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways
PR Newswire · Sep 22, 2026 7:55 AM ET
Lucid Diagnostics (LUCD) Q2 2026 Earnings Call Transcript
Motley Fool · Aug 20, 2026 9:58 AM ET
Lucid Diagnostics Eyes Medicare Catalyst for EsoGuard Growth
MarketBeat · Aug 15, 2026 1:01 AM ET
PAVmed Inc. Q2 2026 Earnings Call Summary
Moby · Aug 14, 2026 4:59 PM ET
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results
PR Newswire · Aug 14, 2026 8:00 AM ET
Lucid Diagnostics Inc. Q2 2026 Earnings Call Summary
Moby · Aug 13, 2026 10:07 PM ET
Lucid Diagnostics Inc (LUCD) (Q2 2026) Earnings Call Highlights: Strategic Pivot to High-Value ...
GuruFocus.com · Aug 13, 2026 7:06 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See LUCD's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.